Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
Docetaxel (DCX) is a highly effective chemotherapeutic drug used in the treatment of different types of cancer, including non-small cell lung cancer (NSCLC). The drug is known to have low oral bioavailability due to its low aqueous solubility, poor membrane permeability and susceptibility to hepatic...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/3/400 |
id |
doaj-6e64ec002a884ff1b93957f9caa84e94 |
---|---|
record_format |
Article |
spelling |
doaj-6e64ec002a884ff1b93957f9caa84e942021-01-23T00:00:57ZengMDPI AGCancers2072-66942021-01-011340040010.3390/cancers13030400Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An OverviewS. Aishah A. Razak0Habibah A. Wahab1Faisalina Ahmad Fisol2Ibrahim M. Abdulbaqi3Thaigarajan Parumasivam4Noratiqah Mohtar5Amirah Mohd Gazzali6School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaDocetaxel (DCX) is a highly effective chemotherapeutic drug used in the treatment of different types of cancer, including non-small cell lung cancer (NSCLC). The drug is known to have low oral bioavailability due to its low aqueous solubility, poor membrane permeability and susceptibility to hepatic first-pass metabolism. To mitigate these problems, DCX is administered via the intravenous route. Currently, DCX is commercially available as a single vial that contains polysorbate 80 and ethanol to solubilize the poorly soluble drug. However, this formulation causes short- and long-term side effects, including hypersensitivity, febrile neutropenia, fatigue, fluid retention, and peripheral neuropathy. DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Hence, the incorporation of DCX into various nanocarrier systems has garnered a significant amount of attention in recent years to overcome these drawbacks. The surfaces of these drug-delivery systems indeed can be functionalized by modification with different ligands for smart targeting towards cancerous cells. This article provides an overview of the latest nanotechnological approaches and the delivery systems that were developed for passive and active delivery of DCX via different routes of administration for the treatment of lung cancer.https://www.mdpi.com/2072-6694/13/3/400docetaxelnanoparticleslung cancerdrug deliverynon-small cell lung cancer (NSCLC) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
S. Aishah A. Razak Habibah A. Wahab Faisalina Ahmad Fisol Ibrahim M. Abdulbaqi Thaigarajan Parumasivam Noratiqah Mohtar Amirah Mohd Gazzali |
spellingShingle |
S. Aishah A. Razak Habibah A. Wahab Faisalina Ahmad Fisol Ibrahim M. Abdulbaqi Thaigarajan Parumasivam Noratiqah Mohtar Amirah Mohd Gazzali Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview Cancers docetaxel nanoparticles lung cancer drug delivery non-small cell lung cancer (NSCLC) |
author_facet |
S. Aishah A. Razak Habibah A. Wahab Faisalina Ahmad Fisol Ibrahim M. Abdulbaqi Thaigarajan Parumasivam Noratiqah Mohtar Amirah Mohd Gazzali |
author_sort |
S. Aishah A. Razak |
title |
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview |
title_short |
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview |
title_full |
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview |
title_fullStr |
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview |
title_full_unstemmed |
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview |
title_sort |
advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-01-01 |
description |
Docetaxel (DCX) is a highly effective chemotherapeutic drug used in the treatment of different types of cancer, including non-small cell lung cancer (NSCLC). The drug is known to have low oral bioavailability due to its low aqueous solubility, poor membrane permeability and susceptibility to hepatic first-pass metabolism. To mitigate these problems, DCX is administered via the intravenous route. Currently, DCX is commercially available as a single vial that contains polysorbate 80 and ethanol to solubilize the poorly soluble drug. However, this formulation causes short- and long-term side effects, including hypersensitivity, febrile neutropenia, fatigue, fluid retention, and peripheral neuropathy. DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Hence, the incorporation of DCX into various nanocarrier systems has garnered a significant amount of attention in recent years to overcome these drawbacks. The surfaces of these drug-delivery systems indeed can be functionalized by modification with different ligands for smart targeting towards cancerous cells. This article provides an overview of the latest nanotechnological approaches and the delivery systems that were developed for passive and active delivery of DCX via different routes of administration for the treatment of lung cancer. |
topic |
docetaxel nanoparticles lung cancer drug delivery non-small cell lung cancer (NSCLC) |
url |
https://www.mdpi.com/2072-6694/13/3/400 |
work_keys_str_mv |
AT saishaharazak advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview AT habibahawahab advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview AT faisalinaahmadfisol advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview AT ibrahimmabdulbaqi advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview AT thaigarajanparumasivam advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview AT noratiqahmohtar advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview AT amirahmohdgazzali advancesinnanocarriersforeffectivedeliveryofdocetaxelinthetreatmentoflungcanceranoverview |
_version_ |
1724327476435353600 |